Glyx 13 Market Trends, Challenges, Opportunities and Forecasts Report to 2023

GLYX-13 (Major Depressive Disorder) Market Size, Share, Global Trends,

Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

GLYX-13 is being developed by Naurex as an adjunctive therapy for MDD in patients with an

inadequate response to antidepressants. The exact MOA of GLYX-13 is not fully understood, but

it is hypothesized that it exerts its antidepressant effects by enhancing synaptic plasticity

(Naurex, press release, December 12, 2013). GLYX-13 is being developed for IV administration

and there is evidence to suggest that the NMDA receptor ligands can demonstrate rapid

antidepressant effects (Popp et al., 2013).

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

For further information on this report, please visit http://www.radiantinsights.com/research/glyx-13-major-depressive-disorder-forecast-andmarket-analysis-to-2023

- Detailed information on GLYX-13 including product description, safety and efficacy profiles

as well as a SWOT analysis.

- Sales forecast for GLYX-13 for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and...